Adverse reactions to duloxetine in depression

Istvan Bitter, Dora Filipovits, Pal Czobor

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: Untreated or inadequately treated depression is the largest risk factor for suicide. However, treatment with different antidepressants can have considerable adverse effects, including the increase of the frequency of suicidal thoughts and behavior. This review summarizes the frequency and severity of adverse events observed during the treatment of depression with duloxetine and considers their relevance to clinical practice. Areas covered: A comprehensive review of the literature was conducted using PubMed and Medline databases listing data published until December 2010. Articles describing safety and tolerability of duloxetine were selected and reference lists of these articles were scrutinized for further relevant papers. In addition, US and EU Summaries of Product Characteristics were studied. Expert opinion: Treatment with duloxetine was associated with mild to moderate adverse events; sexual dysfunction, nausea, headache, dry mouth, somnolence and dizziness being the most frequent among them. No increase in death from suicide and suicidal thoughts and behavior were detected as compared to placebo. So as to avoid discontinuation syndrome as a consequence of abrupt withdrawal of duloxetine, 2 weeks tapering has been recommended before discontinuation. Overall, duloxetine was found to be well tolerated and can be safely administered even in older patients and in those with concomitant illnesses.

Original languageEnglish
Pages (from-to)839-850
Number of pages12
JournalExpert Opinion on Drug Safety
Volume10
Issue number6
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Depression
Suicide
Expert Testimony
Dizziness
PubMed
Nausea
Antidepressive Agents
Headache
Mouth
Therapeutics
Placebos
Duloxetine Hydrochloride
Databases
Safety

Keywords

  • Depression
  • Duloxetine
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Adverse reactions to duloxetine in depression. / Bitter, Istvan; Filipovits, Dora; Czobor, Pal.

In: Expert Opinion on Drug Safety, Vol. 10, No. 6, 11.2011, p. 839-850.

Research output: Contribution to journalArticle

@article{e1b26874f54741e4a38656b002af66f9,
title = "Adverse reactions to duloxetine in depression",
abstract = "Introduction: Untreated or inadequately treated depression is the largest risk factor for suicide. However, treatment with different antidepressants can have considerable adverse effects, including the increase of the frequency of suicidal thoughts and behavior. This review summarizes the frequency and severity of adverse events observed during the treatment of depression with duloxetine and considers their relevance to clinical practice. Areas covered: A comprehensive review of the literature was conducted using PubMed and Medline databases listing data published until December 2010. Articles describing safety and tolerability of duloxetine were selected and reference lists of these articles were scrutinized for further relevant papers. In addition, US and EU Summaries of Product Characteristics were studied. Expert opinion: Treatment with duloxetine was associated with mild to moderate adverse events; sexual dysfunction, nausea, headache, dry mouth, somnolence and dizziness being the most frequent among them. No increase in death from suicide and suicidal thoughts and behavior were detected as compared to placebo. So as to avoid discontinuation syndrome as a consequence of abrupt withdrawal of duloxetine, 2 weeks tapering has been recommended before discontinuation. Overall, duloxetine was found to be well tolerated and can be safely administered even in older patients and in those with concomitant illnesses.",
keywords = "Depression, Duloxetine, Safety, Tolerability",
author = "Istvan Bitter and Dora Filipovits and Pal Czobor",
year = "2011",
month = "11",
doi = "10.1517/14740338.2011.582037",
language = "English",
volume = "10",
pages = "839--850",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Adverse reactions to duloxetine in depression

AU - Bitter, Istvan

AU - Filipovits, Dora

AU - Czobor, Pal

PY - 2011/11

Y1 - 2011/11

N2 - Introduction: Untreated or inadequately treated depression is the largest risk factor for suicide. However, treatment with different antidepressants can have considerable adverse effects, including the increase of the frequency of suicidal thoughts and behavior. This review summarizes the frequency and severity of adverse events observed during the treatment of depression with duloxetine and considers their relevance to clinical practice. Areas covered: A comprehensive review of the literature was conducted using PubMed and Medline databases listing data published until December 2010. Articles describing safety and tolerability of duloxetine were selected and reference lists of these articles were scrutinized for further relevant papers. In addition, US and EU Summaries of Product Characteristics were studied. Expert opinion: Treatment with duloxetine was associated with mild to moderate adverse events; sexual dysfunction, nausea, headache, dry mouth, somnolence and dizziness being the most frequent among them. No increase in death from suicide and suicidal thoughts and behavior were detected as compared to placebo. So as to avoid discontinuation syndrome as a consequence of abrupt withdrawal of duloxetine, 2 weeks tapering has been recommended before discontinuation. Overall, duloxetine was found to be well tolerated and can be safely administered even in older patients and in those with concomitant illnesses.

AB - Introduction: Untreated or inadequately treated depression is the largest risk factor for suicide. However, treatment with different antidepressants can have considerable adverse effects, including the increase of the frequency of suicidal thoughts and behavior. This review summarizes the frequency and severity of adverse events observed during the treatment of depression with duloxetine and considers their relevance to clinical practice. Areas covered: A comprehensive review of the literature was conducted using PubMed and Medline databases listing data published until December 2010. Articles describing safety and tolerability of duloxetine were selected and reference lists of these articles were scrutinized for further relevant papers. In addition, US and EU Summaries of Product Characteristics were studied. Expert opinion: Treatment with duloxetine was associated with mild to moderate adverse events; sexual dysfunction, nausea, headache, dry mouth, somnolence and dizziness being the most frequent among them. No increase in death from suicide and suicidal thoughts and behavior were detected as compared to placebo. So as to avoid discontinuation syndrome as a consequence of abrupt withdrawal of duloxetine, 2 weeks tapering has been recommended before discontinuation. Overall, duloxetine was found to be well tolerated and can be safely administered even in older patients and in those with concomitant illnesses.

KW - Depression

KW - Duloxetine

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=80054753155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054753155&partnerID=8YFLogxK

U2 - 10.1517/14740338.2011.582037

DO - 10.1517/14740338.2011.582037

M3 - Article

C2 - 21545241

AN - SCOPUS:80054753155

VL - 10

SP - 839

EP - 850

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -